gal infection when neutropenia persists for more than 20 days. 5 Following engraftment, the occurrence of graft-verBone marrow transplant (BMT) recipients are at sus-host disease and the use of corticosteroids also increase increased risk of invasive fungal disease as a result of the risk of invasive fungal infections in BMT patients. the profound neutropenia associated with transplanCandida and Aspergillus sp. are the most frequent causes tation. Amphotericin B lipid complex injection (ABLC, of fungal infection in BMT recipients. In a retrospective ABELCET) was developed to preserve the broad specstudy of 1500 patients who underwent BMT, 46 had canditrum and fungicidal activity of conventional amphodemia and 69 had aspergillosis, with respective mortality tericin B while avoiding its associated nephrotoxicity.
11,12
reductions were observed at weeks 1 to 3 (P Ͻ 0.01) Amphotericin B lipid complex injection (ABLC, ABELand 6 (P Ͻ 0.001). Trends in serum creatinine during CET; Liposome, Princeton, NJ, USA) was developed to ABLC therapy between autologous and allogeneic provide a less nephrotoxic alternative to conventional transplant recipients were similar. In summary, the amphotericin B for the treatment of invasive fungal infecresults of this evaluation indicate that ABLC appears tions. 13 The product consists of amphotericin B complexed to be less nephrotoxic than conventional amphotericin with two lipids (dimyristoylphosphatidylcholine and dimyr-B as well as an effective treatment for BMT recipients istoylphosphatidylglycerol) in approximately a 1:1 drug-towith presumed or confirmed fungal infections.
lipid molar ratio. In the complexed state, amphotericin B Keywords: lipid complex; ABLC; nephrotoxicity; bone interacts minimally with mammalian cellular membranes, marrow transplant possibly accounting for its reduced toxicity in vivo. 14, 15 It is believed that phospholipases released by vascular smooth muscle, along with macrophage-derived phospholipases Bone marrow transplantation (BMT) provides hematopoand those released by infecting fungi, break down the lipids ietic rescue to patients undergoing intensive chemotherapy complexed to amphotericin B, thus releasing drug at the for a variety of malignancies as well as for the treatment of focus of infection. hematologic diseases such as aplastic anaemia.
1-3 However, ABLC was made available to investigators on an emerpatients undergoing BMT develop profound neutropenia as gency-use basis to treat seriously ill patients with advanced a result of their intensive myeloablative chemotherapy, 1, 2, 4 systemic fungal infections who had failed treatment with and this is a major predisposing factor in the development systemic antifungal therapy (usually conventional amphoof fungal disease: as many as 40% of patients develop funtericin B), had nephrotoxicity due to amphotericin B or other drugs, or had renal dysfunction that limited the use of amphotericin B. This report describes the efficacy and 
Materials and methods
Mycologic response was defined as eradication -all previously positive specimens were negative for the fungal Study design pathogen; persistence -specimens remained positive, or previously negative specimens became positive; or not evaIn the open-label, multicenter, emergency-use program of luable -data insufficient for assessment. ABLC, patients were enrolled if they had confirmed or presumptive infections and met one of the following criteria: failure of previous amphotericin B treatment at a cumulatEvaluation of safety ive dose of у500 mg (or у7.5 mg/kg), nephrotoxicity
All patients who received at least one dose of ABLC were (у221 mol/l (2.5 mg/dl) in adults or у133 mol/l (1.5 included in the safety analysis. Renal function was usually mg/dl) in children) or other acute toxicity due to amphoassessed daily during therapy by measurement of serum tericin B or other drugs, or pre-existing renal disease that creatinine. Normal serum creatinine values were considered precluded amphotericin B treatment (serum creatinine to be р133 mol/l. Patients were considered to have stable Ͼ265 mol/l (Ͼ3.0 mg/dl) or creatinine clearance Ͻ25
values if the values remained within the normal range or the ml/min).
change from baseline was Ͻ20%. Improvement in serum Patients were excluded from participation based on concreatinine was defined as a decrease from above normal comitant use of any investigational or antiretroviral agent, (у133 mol/l) to within the normal range or Ͼ20% pregnancy or lactation, history of hypersensitivity to decrease from the baseline value. Deterioration in serum amphotericin B, or concomitant condition that precluded creatinine was defined as an increase from within the nortreatment with ABLC. mal range to above normal (у133 mol/l) or Ͼ20% Fungal infections were confirmed on the basis of culture, increase from the baseline value. histology, or (in the case of cryptococcal meningitis) a positive cerebrospinal fluid cryptococcal antigen titer.
A positive culture of respiratory secretions alone was not Results sufficient for the diagnosis of invasive candidosis. Identification of Candida infection was made by one or more blood
Of the patients who enrolled in the emergency-use program, cultures or by one or more cultures from deep tissue sites 95 were bone marrow-transplant recipients with presumed or body spaces that were normally sterile. Alternatively, or confirmed fungal infections (Table 1) . Patient ages invasive candidosis could be confirmed by positive identiranged from 3 to 59 years (mean 33 years). Most patients fication of yeast-like fungi (nonseptate hyphae) upon microwere white (83/95, 87%) and male (58/95, 61%). Patient scopic examination of one or more deep tissue specimens.
weights ranged from 14 to 129 kg (mean 74 kg). Serologic results were only supportive. Invasive candidosis Of the 95 patients, 59 had leukaemia; 13 had solid could not be confirmed by serology alone.
tumours, of which breast cancer was the most common; 11 Invasive aspergillosis was confirmed on the basis of culhad lymphoma; three had anaemia; six had myeloma; and ture or histology. Positive identification of aspergillosis was one patient had bone marrow aplasia, one Chediak-Higashi confirmed by one or more cultures from deep tissue sites, syndrome, and one myelodysplastic syndrome. Seventy-one body spaces, or blood, or by culture of respiratory patients (75%) had an allogeneic transplant, and 24 (25%) secretions, provided chest radiographs were abnormal. As an autologous transplant. Forty-one patients (43%) were an alternative to culture, aspergillosis could also be conneutropenic (Ͻ500/mm 3 ) at baseline. firmed by finding septate hyphae upon microscopic examin-
The mean cumulative dose of ABLC was 6.314 mg ation of one or more deep tissue specimens.
(range 80-40 700 mg), and the mean duration of treatment If culture or histology were negative or not obtainable was 25 days (median 1-198 days). due to the condition of the patient and/or the risk involved in the procedure), but the patient had clinical signs and symptoms consistent with a systemic fungal infection, the Of the 95 BMT recipients, 57 were unevaluable for mycologic efficacy.
assessment. Table 2 Response to ABLC therapy by baseline neutrophil count 
Clinical efficacy
Fifty-nine patients were clinically evaluable for efficacy. riosis, and 100% (1/1) of patients with cryptococcosis. The Thirty-six patients were considered by the investigator to most common types of infection were pulmonary and dishave an undetermined (ie not evaluable) clinical outcome.
seminated: seven of 20 (35%) and 10 of 19 (53%) patients The reasons provided by the investigators included: patient responded to treatment, respectively (Table 4) . received an insufficient number of ABLC doses (n = 20) (19 patients received Ͻ4 doses), patient died due to mulMycologic efficacy tiple factors and an assessment could not be made at the time of death (n = 6), patient had no mycologic evidence For the 38 mycologically evaluable patients, pathogens of an infection (n = 9), and patient had surgical intervention were eradicated in 19 (50%) and persisted in 19 (50%). that precluded assessment (n = 1). All 95 patients were evaOf the 12 mycologically evaluable patients who enrolled luable for safety.
due to nephrotoxicity or acute toxicity, pathogens were Of the 59 evaluable patients, 31 (53%) responded to eradicated for 67% (8/12) ( Table 1) . Among the patients treatment: 23 (39%) were cured and eight (14%) improved.
previously unresponsive to amphotericin B, pathogens were Of the 20 evaluable patients who were enrolled due to eradicated for 42% (10/24). Pathogens were eradicated in nephrotoxicity or acute toxicity, 55% (11/20) responded to 48% (11/23) of allogeneic transplant patients and 53% treatment (Table 1) . Among the patients previously unre-(8/15) of autologous transplant patients. sponsive to amphotericin B, 47% (17/36) responded to Pathogens were eradicated in 45% (9/20) of the patients ABLC therapy.
with aspergillosis and 60% (9/15) of the patients with canEighteen of the 38 evaluable patients (47%) who had didosis (Table 3) . The most common types of infection an allogeneic transplant responded to treatment (Table 1) .
were pulmonary and disseminated: six of 13 (46%) and five Thirteen of the 21 evaluable patients (62%) who had an of 13 (38%) patients had pathogens eradicated (Table 4) . autologous transplant responded to treatment.
Of the 26 evaluable patients who were neutropenic Safety (Ͻ500/mm 3 ) at baseline, 46% (12/26) responded to treatment (Table 2) . Seventeen of the 30 (57%) evaluable Adverse events: All 95 patients were evaluable for safety. patients who were non-neutropenic at baseline responded In general, ABLC appeared to be well tolerated. Ten to treatment. patients (11%) discontinued therapy due to an adverse Of the 29 evaluable patients with aspergillosis, 38% event. Two patients discontinued due to anaemia. One (11/29) responded to treatment (Table 3) . Complete patient in each category discontinued due to the following response or improvement was achieved in 70% (14/20) of events: changes in mental status, bilirubinemia, kidney failpatients with candidosis, 67% (2/3) of patients with fusaure, sepsis, increased serum creatinine, chills, anaphylactoid reaction, or respiratory failure. Since these patients were seriously ill, most of the adverse events appeared to Table 3 Response to ABLC therapy by infection be related to the patient's underlying illness. (0) a Of the 95 BMT recipients, 36 were unevaluable for clinical efficacy. a Adverse events considered related or probably related to study drug with an incidence of Ͼ1%.
b
Of the 95 BMT recipients, 57 were unevaluable for mycologic efficacy. Deteriorated (an increase from within the normal range to у133 mol/l or Ͼ20% increase from the baseline value) 18 (26%) 4 (17%)
Stable (values remained within the normal range or the change from baseline was Ͻ20%) 32 (47%) 14 (61%) Improved (decrease from у133 mol/l to within the normal range or Ͻ20% decrease from the baseline value) 18 (26%) 5 (22%) a Not enough serum creatinine information for three patients to be included in the analysis. b Not enough serum creatinine information for one patient to be included in the analysis.
events considered related or probably related to the study not statistically significant (P Ͼ 0.20). Of the 68 allogeneic bone marrow transplant recipients with serum creatinine drug with an incidence of Ͼ1%. As with conventional amphotericin B, fever and chills were the most common data, 47% (32/68) had stable serum creatinine values during therapy, 26% (18/68) had an improvement in serum creatinadverse events. These may occur 1-2 h after starting an intravenous infusion of ABLC, are more common with the ine, and 26% (18/68) had a deterioration in serum creatinine (Table 6 ). Of the 23 autologous bone marrow transplant first few doses, and generally diminish with subsequent doses.
recipients with serum creatinine data, 61% (14/23) had stable serum creatinine values during therapy, 22% (5/23) had an improvement in serum creatinine, and 17% (4/23) Renal function: Nephrotoxicity was not a major problem with ABLC during the study. Only two patients disconhad a deterioration in serum creatinine (Table 6 ). The baseline mean serum creatinine for 90 patients with tinued therapy due to renal-related adverse events. One patient discontinued due to increased serum creatinine a baseline and end-of-therapy value was 202 mol/l. For these patients, serum creatinine doubled at some point dur-(from 283 mol/l at baseline to a high of 327 mol/l during therapy), and one patient discontinued due to complete ing therapy for 12 (13%) patients; the median time to doubling was 137 days. Of the 24 patients with a serum creatinrenal failure (an increase in serum creatinine from 292 mol/l at baseline to 583 mol/l at the end of therapy).
ine р133 mol/l at baseline, 13 (54%) had an increase to Ͼ133 mol/l at the end of therapy. Of the 24 patients, three Seventy-one patients had an allogeneic bone marrow transplant and 24 had an autologous bone marrow trans-(13%) had an increase in serum creatinine to Ͼ177 mol/l at the end of therapy. plant. There was a higher proportion of patients with serum creatinine deterioration in the allogeneic group compared The baseline mean serum creatinine for the 30 patients who entered the studies with a high baseline value (Ͼ221 to the autologous group (26% vs 17%) mol/l) was 334 mol/l. Figure 1 plots the mean decrease References in serum creatinine over 6 weeks of treatment for these patients. At weeks 1-3 (P р 0.01) and 6 (P Ͻ 0.001), the 
